Biogen (BIIB) Change in Accured Expenses (2009 - 2026)

Biogen has reported Change in Accured Expenses for 18 years, with the latest figure at -$49.7 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses fell 173.08% year-over-year to -$49.7 million in Q2 2026; TTM through Jun 2026 was -$222.2 million, a 41.8% increase from a year earlier, with the FY2025 full-year figure at -$248.0 million, down 38.78% from the prior year.
• Change in Accured Expenses was -$49.7 million for Q2 2026 at Biogen, up from -$243.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.1 billion in Q2 2022, with the low at -$745.7 million in Q4 2022.
• Average Change in Accured Expenses over 5 years is -$57.5 million, with a median of -$72.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 854.76% in 2022, then surged 24864.71% in 2023.
• Over 5 years, Change in Accured Expenses stood at -$745.7 million in 2022, then surged by 33.55% to -$495.5 million in 2023, then soared by 80.93% to -$94.5 million in 2024, then plunged by 127.83% to -$215.3 million in 2025, then jumped by 76.92% to -$49.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$49.7 million (Q2 2026), -$243.2 million (Q1 2026), and -$215.3 million (Q4 2025), per Business Quant data.